Anticanceragent42 (compound 10d) is an orally active, potent anticanceragent with demonstrated efficacy against MDA-MB-231 cells, exhibiting an IC50 of 0.07 μM. It exerts its anticancer activity through the activation of apoptotic pathways and p53 expression. Anticanceragent42 is a valuable tool for investigating metastatic breast cancer [1].
Antibacterial Agent42 demonstrates potent antibacterial activity by effectively reducing the Minimum Inhibitory Concentration (MIC) of the broad-spectrum antibacterial agent Ceftazidime.
Anticanceragent 29 (Compd E Z-6f) exhibits potent anticancer activity, as indicated by IC50 values of 0.054 μM, 0.127 μM, 0.129 μM, and 0.396 μM for CDK2, CDK1, CDK4, and CDK6, respectively [1].
Anticanceragent 70 (Compound 21) is a potent anticancer compound that demonstrates remarkable cytotoxicity against multiple human cancer cell lines. It induces G0/G1-cell cycle arrest and concurrently elevates the levels of p53 and p21 proteins. Furthermore, Anticanceragent 70 induces ATP depletion and disruption of the mitochondrial membrane potential [1].
Anticanceragent 57 (compound 14) demonstrates potent inhibition of MDA-MB-231, MDA-MB-468, and MCF-7 cell lines, with IC 50 values ranging from 6.43 to 8.00 μM. Additionally, this agent induces cell cycle arrest and promotes apoptosis. In vivo studies using nude mice xenografted with MADMB-231 cells have shown that Anticanceragent 57 effectively inhibits tumor growth. Consequently, Anticanceragent 57 can serve as a valuable tool for researching triple negative breast cancer (TNBC) [1].
Anticanceragent 183 (compound 4h) exhibits potent inhibition of matrix metalloproteinase-9 (MMP-9), reducing its viability by more than 75% at a concentration of 100 μg mL. Additionally, it demonstrates significant anticancer activity, with an IC50 value of <0.14 μM against the A549 cell line and induces apoptotic [1] processes.
Anticanceragent 30 (compound 6f-Z) is a potent anticancer compound. It belongs to the class of 3-arylidene-2-oxindole derivatives and acts as a selective inhibitor of CDK2. Extensive research has demonstrated its significant anticancer activity, making it a promising candidate for cancer treatment [1].